Bonacci M, et al. - Experts investigated the long-term clinical and immune system effects of hepatitis C virus eradication with direct-acting antivirals (DAAs) in patients with HCV-cryoglobulinemic vasculitis (CV) and asymptomatic patients with circulating cryoglobulins. It was determined that 42 (91%) had a clinical response among patients with HCV-CV, in that their Birmingham Vasculitis Activity Score (version 3) decreased from 7 to 0. Nevertheless, 5 patients with HCV-CV (11%, 4 with cirrhosis) presented with relapses of vasculitis within 2 years after a sustained viral response to DAA therapy, which comprised of severe organ damage and death.